74
Views
14
CrossRef citations to date
0
Altmetric
Review

Depression and health-related quality of life in patients with rheumatoid arthritis

&
Pages 645-653 | Published online: 09 Jan 2014

References

  • Pocock SJ. A perspective on the role of quality-of-life assessment in clinical trials. Control. Clin. Trials 12(4 Suppl.), S257–S265 (1991).
  • American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 46(2), 328–346 (2002).
  • Akil M, Amos RS. ABC of rheumatology. Rheumatoid arthritis-I: clinical features and diagnosis. Br. Med. J. 310(6979), 587–590 (1995).
  • Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 22(2 Suppl.), 1–12 (2004).
  • Lawrence RC, Helmick CG, Arnett FC et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 41(5), 778–799 (1998).
  • Blumenauer B, Cranney A, Clinch J, Tugwell P. Quality of life in patients with rheumatoid arthritis : which drugs might make a difference? PharmacoEconomics 21(13), 927–940 (2003).
  • Alacron GS. Epidemiology of rheumatoid arthritis. Rheum. Dis. Clin. North Am. 21(3), 589–604 (1995).
  • Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 39(1), 28–33 (2000).
  • Allaire SH, Prashker MJ, Meenan RF. The costs of rheumatoid arthritis. PharmacoEconomics 6(6), 513–522 (1994).
  • Lubeck DP. A review of the direct costs of rheumatoid arthritis: managed care versus fee-for-service settings. Pharmacoeconomics 19(8), 811–818 (2001).
  • Persson LO, Berglund K, Sahlberg D. Psychological factors in chronic rheumatic diseases-a review. The case of rheumatoid arthritis, current research and some problems. Scand. J. Rheumatol. 28(3), 137–144 (1999).
  • Wolfe F. Psychological distress and rheumatic disease. Scand. J. Rheumatol. 28(3), 131–136 (1999).
  • Dickens C, Creed F. The burden of depression in patients with rheumatoid arthritis. Rheumatology (Oxford) 40(12), 1327–1330 (2001).
  • Abdel-Nasser AM, Abd El-Azim S, Taal E, El-Badawy SA, Rasker JJ, Valkenburg HA. Depression and depressive symptoms in rheumatoid arthritis patients: an analysis of their occurrence and determinants. Br. J. Rheumatol. 37(4), 391–397 (1998).
  • Waltz M, Kriegel W, van’t Pad Bosch P. The social environment and health in rheumatoid arthritis: marital quality predicts individual variability in pain severity. Arthritis Care Res. 11(5), 356–374 (1998).
  • Doeglas DM, Suurmeijer TP, van den Heuvel WJ et al. Functional ability, social support, and depression in rheumatoid arthritis. Qual. Life Res. 13(6), 1053–1065 (2004).
  • Katz PP, Yelin EH. Prevalence and correlates of depressive symptoms among persons with rheumatoid arthritis. J. Rheumatol. 20(5), 790–796 (1993).
  • Magni G, Moreschi C, Rigatti-Luchini S, Merskey H. Prospective study on the relationship between depressive symptoms and chronic musculoskeletal pain. Pain 56(3), 289–297 (1994).
  • Dickens C, Jackson J, Tomenson B, Hay E, Creed F. Association of depression and rheumatoid arthritis. Psychosomatics 44(3), 209–215 (2003).
  • Evers AW, Kraaimaat FW, Geenen R, Jacobs JW, Bijlsma JW. Longterm predictors of anxiety and depressed mood in early rheumatoid arthritis: a 3 and 5 year follow-up. J. Rheumatol. 29(11), 2327–2336 (2002).
  • Vali FM, Walkup J. Combined medical and psychological symptoms: impact on disability and healthcare utilization of patients with arthritis. Med. Care 36(7), 1073–1084 (1998).
  • DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch. Intern. Med. 160(14), 2101–2107 (2000).
  • Listing J, Alten R, Brauer D et al. Importance of psychological well being and disease activity in termination of an initial DMARD therapy. J. Rheumatol. 24, 2097–2105 (1997).
  • Bendtsen P, Akerlind I, Hornquist JO. Assessment of quality of life in rheumatoid arthritis: methods and implications. PharmacoEconomics 5(4), 286–298 (1994).
  • Lubeck DP. Patient-reported outcomes and their role in the assessment of rheumatoid arthritis. PharmacoEconomics 22(1 Suppl.), 27–38 (2004).
  • Talamo J, Frater A, Gallivan S, Young A. Use of the short form 36 (SF36) for health status measurement in rheumatoid arthritis. Br. J. Rheumatol. 36 (4), 463–469 (1997).
  • Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum. 43(7), 1478–1487 (2000).
  • Ware JE Jr, Bayliss MS, Rogers WH, Kosinski M, Tarlov AR. Differences in 4-year health outcomes for elderly and poor, chronically ill patients treated in HMO and fee-for-service systems. Results from the Medical Outcomes Study. JAMA 276(13), 1039–1047 (1996).
  • Mathias SD, Colwell HH, Miller DP, Moreland LW, Buatti M, Wanke L. Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clin. Ther. 22(1), 128–139 (2000).
  • Strand V, Scott DL, Emery P et al. Leflunomide Rheumatoid Arthritis Investigators Groups. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J. Rheumatol. 32(4), 590–601 (2005).
  • Durez P, Nzeusseu Toukap A, Lauwerys BR et al. A randomised comparative study of the short-term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. Ann. Rheum. Dis. 63(9), 1069–1074 (2004).
  • Zhao SZ, Fiechtner JI, Tindall EA et al. Evaluation of health-related quality of life of rheumatoid arthritis patients treated with celecoxib. Arthritis Care Res. 13(2), 112–121 (2000).
  • Hunt SM, McKenna SP, McEwen J, Backett EM, Williams J, Papp E. A quantitative approach to perceived health status: a validation study. J. Epidemiol. Community Health 34(4), 281–286 (1980).
  • Sivas F, Ercin O, Tanyolac O, Barca N, Aydog S, Ozoran K. The Nottingham Health Profile in rheumatoid arthritis: correlation with other health status measurements and clinical variables. Rheumatol. Int. 24(4), 203–206 (2004).
  • The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 16(3), 199–208 (1990).
  • Hurst NP, Jobanputra P, Hunter M, Lambert M, Lochhead A, Brown H. Validity of EuroQol-a generic health status instrument-in patients with rheumatoid arthritis. Economic and Health Outcomes Research Group. Br. J. Rheumatol. 33(7), 655–662 (1994).
  • Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br. J. Rheumatol. 36(5), 551–559 (1997).
  • Wolfe F, Hawley DJ. Measurement of the quality of life in rheumatic disorders using the EuroQol. Br. J. Rheumatol. 36(7), 786–793 (1997).
  • Bergner M, Bobbitt RA, Pollard WE, Martin DP, Gilson BS. The sickness impact profile: validation of a health status measure. Med. Care 14(1), 57–67 (1976).
  • Sullivan M, Ahlmen M, Bjelle A. Health status assessment in rheumatoid arthritis. I. Further work on the validity of the sickness impact profile. J. Rheumatol. 17(4), 439–447 (1990).
  • Sullivan M, Ahlmen M, Bjella A et al. Health status assessment in rheumatoid arthritis: II. Evaluation of a modified Shorter Sickness Impact Profile. J. Rheumatol. 20, 1500–1507 (1993).
  • Meenan RF, Gertman PM, Mason JH. Measuring health status in arthritis. The arthritis impact measurement scales. Arthritis Rheum. 23(2), 146–152 (1980).
  • Salaffi F, Stancati A, Carotti M. Responsiveness of health status measures and utility-based methods in patients with rheumatoid arthritis. Clin. Rheumatol. 21(6), 478–487 (2002).
  • Guillemin F. Functional disability and quality-of-life assessment in clinical practice. Rheumatology (Oxford) 39(Suppl. 1), 17–23 (2000).
  • Fitzpatrick R, Ziebland S, Jenkinson C, Mowat A, Mowat A. A generic health status instrument in the assessment of rheumatoid arthritis. Br. J. Rheumatol. 31(2), 87–90 (1992).
  • de Jong Z, van der Heijde D, McKenna SP, Whalley D. The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument. Br. J. Rheumatol. 36(8), 878–883 (1997).
  • Quinn MA, Conaghan PG, O’Connor PJ et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 52(1), 27–35 (2005).
  • Ware JE Jr, Keller SD, Hatoum HT et al. The SF-36 Arthritis-Specific Health Index (ASHI): I. Development and cross-validation of scoring algorithms. Med. Care 37(5 Suppl.), MS40–MS50 (1999).
  • Verhoeven AC, Boers M, van der Liden S. Validity of the MACTAR questionnaire as a functional index in a rheumatoid arthritis clinical trial. The McMaster Toronto Arthritis. J. Rheumatol. 27(12), 2801–2809 (2000).
  • Nichol MB, Harada AS. Measuring the effects of medication use on health-related quality of life in patients with rheumatoid arthritis. PharmacoEconomics 16(5 Pt 1), 433–448 (1999).
  • Goldney RD, Phillips PJ, Fisher LJ, Wilson DH. Diabetes, depression, and quality of life: a population study. Diabetes Care 27(5), 1066–1070 (2004).
  • Fossa SD, Dahl AA. Short Form 36 and Hospital Anxiety and Depression Scale. A comparison based on patients with testicular cancer. J. Psychosom. Res. 52(2), 79–87 (2002).
  • Vazquez I, Valderrabano F, Fort J et al. Spanish Co-operative Renal Patients Quality of Life Study Group. Psychosocial factors and health-related quality of life in hemodialysis patients. Qual. Life Res. 14(1), 179–190 (2005).
  • Escalante A, del Rincon I. How much disability in rheumatoid arthritis is explained by rheumatoid arthritis? Arthritis Rheum. 42(8), 1712–1721 (1999).
  • Mikuls T, Saag K, Criswell L, Merlino L, Cerhan JR. Health related quality of life in women with elderly onset rheumatoid arthritis. J. Rheumatol. 30(5), 952–957 (2003).
  • Rupp I, Boshuizen HC, Jacobi CE, Dinant HJ, van den Bos GA. Impact of fatigue on health-related quality of life in rheumatoid arthritis. Arthritis Rheum. 51(4), 578–585 (2004).
  • Murphy H, Dickens C, Creed F, Bernstein R. Depression, illness perception and coping in rheumatoid arthritis. J. Psychosom. Res. 46(2), 155–164 (1999).
  • Hawley DJ. Psycho-educational interventions in the treatment of arthritis. Baillieres Clin. Rheumatol. 9(4), 803–823 (1995).
  • Riemsma RP, Taal E, Kirwan JR, Rasker JJ. Systematic review of rheumatoid arthritis patient education. Arthritis Rheum. 51(6), 1045–1059 (2004).
  • Brady TJ, Kruger J, Helmick CG, Callahan LF, Boutaugh ML. Intervention programs for arthritis and other rheumatic diseases. Health Educ. Behav. 30(1), 44–63 (2003).
  • Mullen PD, Laville EA, Biddle AK, Lorig K. Efficacy of psychoeducational interventions on pain, depression, and disability in people with arthritis: a meta-analysis. J. Rheumatol. 14(Suppl. 15), 33–39 (1987).
  • Riemsma RP, Kirwan JR, Taal E, Rasker JJ. Patient education for adults with rheumatoid arthritis. Cochrane Database Syst. Rev. (2), CD003688 (2003).
  • Sharpe L, Sensky T, Timberlake N, Ryan B, Brewin CR, Allard S. A blind, randomized, controlled trial of cognitive-behavioural intervention for patients with recent onset rheumatoid arthritis: preventing psychological and physical morbidity. Pain 89(2–3), 275–283 (2001).
  • Sharpe L, Sensky T, Timberlake N, Ryan B, Allard S. Long-term efficacy of a cognitive behavioural treatment from a randomized controlled trial for patients recently diagnosed with rheumatoid arthritis. Rheumatology (Oxford) 42(3), 435–441 (2003).
  • Evers AW, Kraaimaat FW, van Riel PL, de Jong AJ. Tailored cognitive-behavioral therapy in early rheumatoid arthritis for patients at risk: a randomized controlled trial. Pain 100(1–2), 141–153 (2002).
  • Ash G, Dickens CM, Creed FH, Jayson MI, Tomenson B. The effects of dothiepin on subjects with rheumatoid arthritis and depression. Rheumatology (Oxford) 38(10), 959–967 (1999).
  • Bird H, Broggini M. Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double-blind, parallel group study. J. Rheumatol. 27(12), 2791–2797 (2000).
  • Frank RG, Kashani JH, Parker JC et al. Antidepressant analgesia in rheumatoid arthritis. J. Rheumatol. 15(11), 1632–1638 (1988).
  • Sarzi Puttini P, Cazzola M, Boccassini L et al. A comparison of dothiepin versus placebo in the treatment of pain in rheumatoid arthritis and the association of pain with depression. J. Int. Med. Res. 16(5), 331–337 (1988).
  • Parker JC, Smarr KL, Slaughter JR et al. Management of depression in rheumatoid arthritis: a combined pharmacologic and cognitive-behavioral approach. Arthritis Rheum. 49(6), 766–777 (2003).
  • Wolfe F, Pincus T. Listening to the patient: a practical guide to self-report questionnaires in clinical care. Arthritis Rheum. 42(9), 1797–1808 (1999).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.